Sigyn Therapeutics (SIGY) Non-Current Debt (2017 - 2025)

Sigyn Therapeutics (SIGY) posted Non-Current Debt of $2.1 million for Q3 2025, up 9.07% sequentially from $1.9 million in Q4 2024.

Sigyn Therapeutics (SIGY) Non-Current Debt (2017 - 2025) Analysis & Trends

Sigyn Therapeutics has reported Non-Current Debt for 4 years, with the latest figure at $2.1 million in Q3 2025.

Quarterly Non-Current Debt changed N/A year-over-year to $2.1 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $2.1 million (changed N/A YoY) and the FY2024 annual result came in at $1.9 million, changed N/A from the prior year.
Non-Current Debt climbed to $2.1 million in Q3 2025 per SIGY's latest filing, from $1.9 million in the prior quarter.
Over five years, Non-Current Debt peaked at $2.1 million in Q3 2025 and troughed at $1.9 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	8.96 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	360.97 Mn
10	Sigyn Therapeutics	48,161.31	-37,409.69	-	2.51 Mn

Download Data